Eidogen-Sertanty Announces Worldwide Technology Licensing Agreement with Pfizer

San Diego, CA (September 20, 2006) – Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, today announced a worldwide technology licensing agreement with Pfizer Inc, encompassing Eidogen-Sertanty’s drug discovery software and database technology.

Under the terms of the agreement, Pfizer will obtain worldwide access to Eidogen-Sertanty’s suite of discovery informatics technologies, including the TIP Structural Knowledgebase, EVE Comparative Visualizer, Chemical Intelligence Platform (ChIP), and Activity-Reaction-Knowledge Archival system (ARK). In addition, Pfizer has licensed access to the core algorithms of TIP, including STRUCTFAST, SiteSeeker, StructSorter, and SiteSorter.

“We are very excited about our ongoing alliance with Pfizer.  The deal represents an expansion of Eidogen-Sertanty’s relationship with Pfizer, which began in early 2005,” said Steve Muskal, CEO of Eidogen-Sertanty.  “Our relationship and global licensing arrangement with the world’s largest pharmaceutical company demonstrate our products’ significant role in drug discovery research."

About Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations.  Eidogen-Sertanty’s unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization.  To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com.

Contact Information:
Steve Muskal
760-729-0211
pr@eidogen-sertanty.com